Drugs / AVLX-144
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04689035 | Sep 2020 → Jul 2023 | — | Avilex Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-05-26 | Avilex Pharma | Results Successfully completes phase 1 clinical trial avilexpharma.com ↗
During the course of the Phase I study, AVLX-144 was well-tolerated and demonstrated no noteworthy safety issues related to treatment |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-17 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere and Avilex Pharma Announce Strategic Regional Licensing Partnership to Develop and Commercialize AVLX-144 for the Treatment of Acute Ischemic Stroke (AIS) in Greater China simcere.com ↗ |
| 2021-05-26 | Avilex Pharma | Successfully completes phase 1 clinical trial avilexpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVLX-144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04689035 ↗ |
| Route | Intravenous | “Intravenously Administered AVLX-144” NCT04689035 ↗ |